Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Clearside Biomedical, Inc. (CLSDQ : OTC)

• Company Description    Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. Number of Employees: 32

• Price / Volume Information    Yesterday's Closing Price: $0.32 Daily Weekly Monthly 20 Day Moving Average: 6,771 shares Shares Outstanding: 5.23 (millions) Market Capitalization: $1.65 (millions) Beta: 1.86 52 Week High: $4.57 52 Week Low: $0.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.65% -3.32% 12 Week -45.67% -49.78% Year To Date -55.30% -59.57%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 900 NORTH POINT PARKWAY SUITE 200 - ALPHARETTA,GA 30005 USA ph: 678-270-3631 fax: 678-270-4033 ir@clearsidebio.com http://www.clearsidebio.com

• General Corporate Information    Officers George Lasezkay - President; Chief Executive Officer and Director Charles A. Deignan - Chief Financial Officer Anthony S. Gibney - Director Richard Croarkin - Director Jeffrey L. Edwards - Director Peer Information Clearside Biomedical, Inc. (CORR.) Clearside Biomedical, Inc. (RSPI) Clearside Biomedical, Inc. (CGXP) Clearside Biomedical, Inc. (BGEN) Clearside Biomedical, Inc. (GTBP) Clearside Biomedical, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 185063203 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 05/27/26 Share - Related Items Shares Outstanding: 5.23 Most Recent Split Date: 9.00 (0.07:1) Beta: 1.86 Market Capitalization: $1.65 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 05/27/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: 0.50 EPS Growth vs. Year Ago Period: 23.96% vs. Previous Quarter: -26.73% Sales Growth vs. Year Ago Period: -80.64% vs. Previous Quarter: -59.15% ROE 03/31/26 - - 12/31/25 - - 09/30/25 - - ROA 03/31/26 - - 12/31/25 - - 09/30/25 - -144.89 Current Ratio 03/31/26 - - 12/31/25 - - 09/30/25 - 2.98 Quick Ratio 03/31/26 - - 12/31/25 - - 09/30/25 - 2.98 Operating Margin 03/31/26 - - 12/31/25 - - 09/30/25 - -780.90 Net Margin 03/31/26 - - 12/31/25 - - 09/30/25 - -780.90 Pre-Tax Margin 03/31/26 - - 12/31/25 - - 09/30/25 - -759.45 Book Value 03/31/26 - - 12/31/25 - - 09/30/25 - -10.30 Inventory Turnover 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Equity 03/31/26 - - 12/31/25 - - 09/30/25 - - Debt-to-Capital 03/31/26 - - 12/31/25 - - 09/30/25 - -

Powered by Zacks Investment Research ©